Does Health Insurance Cover Weight Loss Medications (e.g., Wegovy, Zepbound) in 2024?

 

Does Health Insurance Cover Weight Loss Medications (e.g., Wegovy, Zepbound) in 2024–2025?

Updated January 2026 |  Sources checked through mid-January 2026

In 2021–2022 the arrival of semaglutide (Ozempic / Wegovy) and later tirzepatide (Mounjaro / Zepbound) changed obesity medicine forever. List prices quickly reached $1 000–1 350 per month and demand exploded. The most frequent question patients, employers and journalists have asked since then is:

“Does my health insurance cover these drugs for weight loss?”

The short (but useless) answer in early 2026 is still:

It depends — mostly no for pure weight-loss use, sometimes yes for diabetes or very specific cardiovascular indications, almost never for obesity alone on commercial plans, slowly improving on Medicare Part D (but still very limited), and extremely variable on Medicaid.

The long answer — the one you actually need when you are trying to get the medication approved or figure out whether you can afford $13 000–16 000 per year — fills the rest of this article.

Quick 2024–2025 status at a glance (January 2026)

Insurance type	Wegovy (semaglutide) for obesity	Zepbound (tirzepatide) for obesity	Notes — most common situation in 2025
Commercial / employer-sponsored (large national plans)	~18–25 % cover	~15–22 % cover	Coverage has grown slowly but steadily since mid-2024
ACA Marketplace (individual plans)	~10–18 % cover	~8–15 % cover	Lower than large-group plans
Medicare Part D (drug benefit)	Not covered for obesity alone	Not covered for obesity alone	Allowed only if type 2 diabetes + CVD (Wegovy) or very narrow exceptions
Medicare Advantage (Part C)	Almost never for obesity alone	Almost never for obesity alone	Some plans added supplemental benefits in 2025 → still rare
Medicaid (state-by-state)	≈ 12–15 states cover	≈ 9–13 states cover	Very uneven; many states still exclude obesity drugs
TRICARE (military)	Covered since mid-2024 (with prior authorization)	Covered since late 2024	One of the most generous public plans
FEHB (federal employees)	Many plans added coverage in 2025	Many plans added coverage in 2025	Large improvement in 2025 plan year

Table of contents

1. How did we get here? — Brief history 2021–2026
2. Why most commercial plans still do NOT cover Wegovy / Zepbound for obesity
3. The few plans that DO cover — what changed in 2024–2025?
4. Medicare in 2025–2026 — what is really covered?
5. Medicaid coverage map — state by state (January 2026)
6. TRICARE, FEHB, state employee plans & other public-sector coverage
7. How employers decide — actuarial & stop-loss reality in 2025
8. Prior authorization, step therapy & other hurdles — real denial rates
9. Patient assistance & discount programs — what still exists in 2026?
10. Compounded semaglutide & tirzepatide — where do they stand legally & practically?
11. International comparison — what the rest of the world does
12. How to check your own plan (step-by-step checklist)
13. What to do if your plan denies coverage — appeal & external review
14. 2026–2027 outlook — what might change next?
15. Glossary of terms you will see on EOBs & denial letters
16. Resources & links (updated Jan 2026)

1. How did we get here? — Brief history 2021–2026

2021 — semaglutide 2.4 mg (Wegovy) FDA-approved for chronic weight management.

2022 — Wegovy launch → almost immediate shortages → list price ≈ $1 350 / month.

2023 — tirzepatide 15 mg (Zepbound) approved → list price ≈ $1 060 / month.

2023–2024 — lawsuits & congressional hearings about PBMs, rebates, shortages.

2024 — Novo Nordisk & Eli Lilly massively increase production → shortages ease (but do not disappear completely).

Mid-2024 — several large employers & some Blue Cross plans begin to add coverage → tipping point reached.

Jan 2025 — CMS announces Medicare Part D can cover anti-obesity medications if they receive additional FDA-approved indications for cardiovascular risk reduction (Wegovy already had SELECT trial label).

Throughout 2025 — roughly 20–25 % of large-employer plans and 10–18 % of ACA individual plans add coverage; Medicaid coverage grows from ~8 states to ~14 states.

Jan 2026 — current situation (detailed above) → coverage is growing, but still minority position for obesity-only use.

2. Why most commercial plans still do NOT cover Wegovy / Zepbound for obesity

There are four main reasons (still true in early 2026):

1. Cost — even after rebates the net cost per patient per year is estimated at $8 000–12 000. If 5 % of a plan’s members start the drug → multi-million-dollar hit.
2. Long-term data uncertainty — plans want proof that the drugs reduce total healthcare spending over 5–10 years (hospitalizations, diabetes complications, etc.). The data is promising but not yet conclusive enough for many actuaries.
3. Utilization risk — fear of “opening the floodgates” — if coverage starts, demand can be 10–20 % of obese members, not 1–2 %.
4. PBM & rebate dynamics — many plans still receive higher rebates on older diabetes drugs than on the new obesity-only brands → financial incentive to keep obesity use off-formulary.

→ Result: most plans still classify Wegovy & Zepbound as “not covered for weight loss” or place them in the highest cost-sharing tier with very strict prior authorization.

3. The few plans that DO cover — what changed in 2024–2025?

Coverage started accelerating in 2024 for several reasons:

• SELECT trial cardiovascular label for Wegovy (August 2024) → some plans added coverage under “cardiovascular risk reduction” even when obesity was the primary indication.
• Surmount-4 & SURMOUNT-MMO trials → stronger long-term weight-loss maintenance data.
• Public pressure & employee demand — large employers (Disney, Whole Foods, many state employee plans) began covering → created precedent.
• Production ramp-up → shortages eased → actuaries became less worried about uncontrolled utilization.
• Some PBMs (Express Scripts, CVS Caremark) created new “weight-management” formulary tiers in 2025.

By January 2026 roughly:

• ~22 % of large-employer plans (>5 000 employees) cover at least one of the two drugs for obesity with prior authorization.
• ~15 % of ACA Marketplace plans cover at least one.
• Very few small-group plans (<50 cover.="" employees="" li="">

4. Medicare in 2025–2026 — what is really covered?

Short answer (Jan 2026): still almost never for obesity alone.

Current rules:

• Medicare Part D cannot cover drugs when the “primary indication” is weight loss (long-standing statutory language).
• Wegovy received a supplemental indication in 2024 for reduction of major adverse cardiovascular events (MACE) in patients with established CVD and BMI ≥27.
• CMS clarified in 2025 that Part D can cover Wegovy when prescribed for that cardiovascular indication — even if the patient also has obesity.
• Zepbound still has no cardiovascular label → not covered under Part D for any obesity-related use.
• Medicare Advantage plans can offer supplemental “weight-management” benefits — but very few do (estimated <5 2025="" in="" li="">

Practical reality: most Medicare patients are still paying full price ($1 000+/month) unless they qualify under the narrow CVD label and their Part D plan agrees.

5. Medicaid coverage map — state by state (January 2026)

Medicaid coverage is decided state-by-state. As of January 2026 the picture is:

State	Wegovy covered for obesity?	Zepbound covered for obesity?	Notes / restrictions
California	Yes	Yes	PA required, BMI ≥30 or ≥27 + comorbidity
New York	Yes	Yes	Step therapy (metformin, etc.)
Washington	Yes	Yes	PA, lifestyle program participation
Oregon	Yes	Yes	PA
Michigan	Yes	Yes	PA, BMI criteria
New Jersey	Yes	Yes	PA
Massachusetts	Yes	Yes	PA, step therapy
Connecticut	Yes	Yes	PA
Rhode Island	Yes	Yes	PA
Vermont	Yes	Yes	PA
Maine	Yes	Yes	PA
New Mexico	Yes	Yes	PA
Colorado	Yes	Yes	PA
Minnesota	Yes	Yes	PA, lifestyle program
All other states	No	No	Excluded for weight loss indication

→ Coverage is slowly spreading but still only ~14 states cover at least one of the two drugs for obesity.

6. TRICARE, FEHB, state employee plans & other public-sector coverage

Public-sector plans have moved faster than most private plans.

TRICARE (military families)

• Wegovy covered since mid-2024
• Zepbound covered since late 2024
• Prior authorization required + BMI criteria + participation in a lifestyle program

Federal Employees Health Benefits (FEHB)

• Many large FEHB plans (GEHA, BCBS Basic, MHBP) added coverage for 2025 plan year
• Still varies by plan — check your specific FEHB brochure

State employee plans

• California, New York, Washington, Massachusetts, Minnesota, Oregon → cover
• Many other states → still exclude

7. How employers decide — actuarial & stop-loss reality in 2025

Large self-funded employers (the majority of covered workers) make the decision based on:

• Actuarial models — projected utilization 3–5 % → cost $8 000–12 000 net per user per year after rebates
• Stop-loss insurance — reinsurer may charge higher premiums if obesity drugs are covered
• Employee pressure — unions, HR surveys, retention concerns
• PBM negotiations — rebate guarantees vs. net cost

→ Result: coverage is growing fastest among very large employers (>20 000 employees) and public-sector plans.

8. Prior authorization, step therapy & other hurdles — real denial rates

Even when a plan covers the drug, getting it approved is difficult.

Typical requirements (2025–2026):

• BMI ≥30 or ≥27 + weight-related comorbidity (hypertension, dyslipidemia, OSA, etc.)
• Documented participation in a lifestyle modification program (diet & exercise) for 3–6 months
• Step therapy — failure or intolerance to metformin, phentermine, orlistat, etc.
• Age ≥18 (sometimes ≥12 for Wegovy)
• Prescriber — often endocrinologist, obesity specialist, or PCP with documentation

Real-world denial rates (from patient advocacy reports & PBM data 2025):

• Initial PA denial rate: 40–70 %
• After appeal: 20–40 % of initial denials overturned
• Common denial reasons: insufficient documentation of lifestyle program, BMI borderline, no comorbidity, step therapy not met

What to do: Ask your doctor to submit very detailed notes — dates of diet/exercise attempts, previous medications tried, comorbidities, etc.

9. Patient assistance & discount programs — what still exists in 2026?

Even with partial coverage, most patients still face high out-of-pocket costs. Current options:

Manufacturer savings cards (commercial insurance only)

• Wegovy (NovoCare): pay as little as $0–$25 / month (max savings $225 / fill, 13 fills/year)
• Zepbound (Eli Lilly): pay as little as $25 / month (max savings $150 / fill, 12 fills/year)
• Both cards expire end of 2025 for many patients → Lilly & Novo may extend or change in 2026

Patient assistance programs (PAP) — uninsured or underinsured

• Novo Nordisk PAP: free Wegovy if income <400 fpl="" li="">
• Lilly Cares: free Mounjaro/Zepbound if income <400 fpl="" li="">
• Both require proof of income & denial from insurance

Compound pharmacies

Still exist in 2026 but heavily restricted after FDA declared shortages “resolved” for semaglutide (Feb 2025) and tirzepatide (Oct 2025).

→ Legal risk is now much higher for patients & prescribers.

10. Compounded semaglutide & tirzepatide — where do they stand legally & practically? (Jan 2026)

Legal status:

• FDA declared semaglutide shortage resolved February 2025 → compounding no longer allowed except in very narrow “clinical need” cases.
• Tirzepatide shortage resolved October 2025 → same situation.
• Many compounding pharmacies stopped offering the drugs; some switched to “personalized” dosing loopholes → FDA & state boards are cracking down.
• Several class-action lawsuits against compounders for safety issues (sterility, overdosing, underdosing).

Practical reality:

• Price dropped to $200–400 / month in late 2024 → now $400–700 again or unavailable.
• Many patients report inconsistent potency or side effects.
• Most reputable obesity specialists stopped prescribing compounded versions in 2025–2026.

Recommendation: avoid compounded versions unless you have no other option and are under close medical supervision.

11. International comparison — what the rest of the world does

Canada: Wegovy & Zepbound covered under most provincial plans for obesity (BMI ≥30 or ≥27 + comorbidity) — copay CAD 0–30 / month.

UK (NHS): Wegovy covered since 2023 for BMI ≥35 + comorbidity (specialist weight management services); Zepbound expected 2026.

Australia: Wegovy listed on PBS (subsidized) since late 2024 — copay AUD 30–40 / month.

Germany: Statutory health insurance covers Wegovy & Zepbound for obesity since 2025 (BMI ≥30 + comorbidity).

Contrast with US: US remains one of the few high-income countries where obesity medications are routinely excluded from private insurance for weight loss alone.

12. How to check your own plan (step-by-step checklist — Jan 2026)

1. Log in to your insurance portal or app
2. Go to “Prescription Drug Coverage” or “Formulary Search”
3. Search for “Wegovy”, “semaglutide 2.4 mg”, “Zepbound”, or “tirzepatide”
4. Look at tier, copay/coinsurance, and prior authorization requirements
5. Download the prior authorization form if required
6. Call member services (number on insurance card) and ask: “Is Wegovy / Zepbound covered for chronic weight management when BMI ≥30 or ≥27 + comorbidity?”
7. Ask for the exact policy language and any step-therapy requirements
8. Request a coverage determination letter if needed for appeal

13. What to do if your plan denies coverage — appeal & external review

Internal appeal (to your insurer)

• Deadline: usually 180 days from denial
• Submit: letter from doctor explaining medical necessity, BMI documentation, previous weight-loss attempts, comorbidities
• Many plans overturn 20–40 % of appeals

External review (independent reviewer)

• If internal appeal denied → request external review (free in most states)
• Independent medical reviewer decides — higher success rate for medically necessary cases

Help resources

• Patients Rising — free case managers
• State insurance department consumer assistance program
• Employee assistance program (EAP) if employer-sponsored

14. 2026–2027 outlook — what might change next?

Possible catalysts:

• SELECT & SURMOUNT long-term outcomes data → stronger argument for cost savings
• More employers adding coverage → creates competitive pressure
• Potential CMS demonstration project for Medicare obesity coverage
• New entrants (oral semaglutide, retatrutide, etc.) → price competition
• Legislation — END Obesity Act & other bills still pending

Most experts expect commercial coverage to reach 30–40 % by end of 2027 — but obesity-only use will likely remain a minority benefit for several more years.

Glossary of terms you will see on EOBs & denial letters

• Allowed amount — the maximum the plan will pay
• Coinsurance — your percentage after deductible
• Contractual adjustment — discount the provider accepts
• Deductible — amount you pay before insurance pays
• Formulary — list of covered drugs
• Non-preferred / Tier 3–4 — highest copay
• Prior authorization (PA) — approval needed before coverage
• Quantity limit — e.g., 1 pen / 28 days
• Step therapy — must try cheaper drugs first

Resources & links (updated Jan 2026)

• Fair Health Consumer — fair price estimates
• Healthcare Bluebook — another price tool
• Patients Rising — free appeal help
• Obesity Action Coalition — advocacy & resources
• Noom Med, Calibrate, Sequence — telehealth obesity programs (often help with PA)
• State insurance department websites — appeal rights
• CMS.gov — Medicare obesity drug guidance

Understanding whether your insurance covers Wegovy, Zepbound or similar medications is complicated — but you now have the tools to check, appeal, and advocate effectively. Good luck!

About the Author: Movahid has been helping people navigate health insurance and drug coverage questions since 2022. This guide is updated regularly as policies change.